ID: MRFR/Pharma/7003-HCR | 140 Pages | Published By Rahul Gotadki on March 2023
Hyperhidrosis Treatment Market is expected to hold a value of USD 1365.39 Million By 2030 at a CAGR of 5.90%
The Hyperhidrosis Treatment Market is anticipated to reach USD 1365.39 Million by 2030 at 5.90% CAGR during the forecast period 2022-2030.Despite being one of the most commonly occurring conditions, the hyperhidrosis treatment market continues to grow at a moderate rate. Antiperspirants and topical products are the first line of treatment in the hyperhidrosis treatment market. However, there is no permanent cure to hyperhidrosis yet. However, there has been high activity in terms of technological developments and product developments in the past few years. Also, with growing awareness about the treatment options and patient’s inclination towards novel approaches has been an encouraging factor for the companies to invest in this market.
Hyperhidrosis Treatment Market Influencer
The increasing usage of botulinum toxin for the treatment of hyperhidrosis has been instrumental in boosting the market growth. The rising number of products by key players in the market are likely to act as a promising factor for the growth of the hyperhidrosis treatment market.
Hyperhidrosis Treatment Market Segmentation
Hyperhidrosis Treatment Market Key Players
|Market Size||2030: USD 1365.39 Million|
|Forecast Units||Value (USD Million)|
|Report Coverage||Revenue Forecast, Competitive Landscape, Growth Factors, and Trends|
|Segments Covered||Type, Treatment, End user, Region|
|Geographies Covered||North America, Europe, Asia-Pacific, and Rest of the World (RoW)|
|Key Vendors||Brickell Biotech Inc. (US), Allergan PLC (Ireland), Cynosure (US), Dermira Inc. (US), Dermadry Laboratories inc. (Canada), GlaxoSmithKline PLC (UK), Sesderma (Spain), Miramar Labs, Inc. (US), and Ulthera Inc. (US)|
|Key Market Opportunities||Rising number of products by key players in the market|
|Key Market Drivers||
hyperhidrosis treatment market is projected grow at approximately 5.90% CAGR during the assessment period (2022-2030).
The valuation of the global hyperhidrosis treatment market is estimated to increase to USD 1365.39 Million by the end of 2030.
By type, the primary hyperhidrosis segment and by treatment, the topical treatment segment segment holds the majority shares in the global hyperhidrosis treatment market.
North America holds the largest share in the global hyperhidrosis treatment market, followed by Europe and the Asia Pacific, respectively.
Brickell Biotech Inc. (US), Allergan PLC (Ireland), Cynosure (US), Dermira Inc. (US), Dermadry Laboratories inc. (Canada), GlaxoSmithKline PLC (UK), Sesderma (Spain), Miramar Labs, Inc. (US), and Ulthera Inc. (US), are some of the major players operating in the global hyperhidrosis treatment market.